Searchable abstracts of presentations at key conferences in endocrinology

ea0016oc1.4 | Neuroendocrinology and pituitary | ECE2008

Pasireotide (SOM230) effectively reduces pituitary tumor volume in patients with active acromegaly: preliminary 6-month results from a phase II extension study

Farrall Andrew J , Glusman Joan E , Ruffin Matthieu , Petersenn Stephan

Introduction: In a recent 16-week Phase II study in patients with de novo, persistent or recurrent acromegaly, pasireotide effectively controlled GH and/or IGF-I levels in 56% of patients, and reduced tumor volume by >20% in 39% of patients. We present preliminary 6-month results from the ongoing extension phase of this study.Methods: This extension study enrolled patients who achieved biochemical control (GH ≤2.5 μg/l and normalize...

ea0014p565 | (1) | ECE2007

The effects of pasireotide (SOM230) on glucose metabolism and growth hormone (GH) nadir during oral glucose tolerance test (OGTT) in 12 patients with acromegaly from a Phase II study

Petersenn Stephan , Glusman Joan , Unger Nicole , Mann Klaus

Introduction: Pasireotide (SOM230) is a novel multi-ligand somatostatin analogue with high binding affinity for four of the five somatostatin receptor subtypes (sst1,2,3 and sst5). A randomized study of 59 patients showed that pasireotide effectively controls GH and IGF-I levels in patients with acromegaly and reduces pituitary tumor size. The impact of pasireotide on GH levels during glucose suppression and glucose metabolism in 12 patients enrolled in t...

ea0016s24.4 | State of the art in the therapy of pituitary disease | ECE2008

Development of a disease-related QoL-questionnaire for Cushing’s disease

Webb Susan M , Badia Xavier , Barahona Maria-Jose , Colao Annamaria , Strasburger Christian J , Tabarin Antoine , van Aken Maarten , Pivonello Rosario , Stalla Gunther , Lamberts Steven W J , Glusman Joan

Chronic exposure to hypercortisolism significantly impacts on patient’s health and health-related quality of life (HRQoL). We developed a disease-generated questio-nnaire to evaluate HRQoL in Cushing’s syndrome (CS) (CushingQoL); in 125 (104 females) patients recruited in Spain, France, Germany, The Netherlands and Italy, clinical and hormonal data were collected and correlated with results of the generic SF-36 questionnaire, a question on self-perceived general heal...

ea0014p559 | (1) | ECE2007

Development and validation of a questionnaire to evaluate health-related quality of life in patients with Cushing’s syndrome

Webb Susan M , Badia Xavier , Barahona Maria- Jose , Colao Annamaria , Strasburger Christian J , Tabarin Antoine , Aken MO van , Pivonello Rosario , Stalla Gunther , Chabre O , Lamberts Steven WJ , Glusman Joan E

Chronic exposure to hypercortisolism has a significant impact on patient’s health and Health-Related Quality of Life (HRQoL), as demonstrated with generic questionnaires. Objective: Develop and validate a disease-generated questionnaire to evaluate HRQoL in patients with Cushing’s syndrome-CS- (Cushing QoL). Methods: After a literature review, interviews with expert endocrinologists and 10 patients identified HRQoL domains and clinical aspects of the disease; an anal...